Symposium ArticlesEvolving Treatment Strategies for the Management of Type 2 Diabetes
Section snippets
TRADITIONAL APPROACH TO TREATMENT
To achieve the suggested glycemic targets for glucose control of T2DM, lifestyle intervention, that is, diet and exercise, has traditionally been the first step. However, diabetes is a progressive disease that is characterized not only by the presence of insulin resistance but also by the abnormalities in hepatic glucose production (HGP) and a progressive decline in β-cell function over time.9 To treat patients with T2DM effectively, the provider must have a good understanding of both the
EVOLVING TREATMENTS
As outlined earlier and recently reviewed in detail, available treatments for patients with T2DM include oral medications—including secretagogues, such as sulfonylureas and “glinides” (repaglinide and nateglinide); metformin; TZDs and dipeptidyl peptidase-4 (DPP-4) inhibitors—and parenterally administered agents, for example, insulin and glucagon-like peptide-1 (GLP-1) receptor agonists.9., 10., 11. Clearly, the traditional agents, such as sulfonylureas, insulin and metformin, have served
PHYSIOLOGIC ROLE OF INCRETINS
Two major incretin hormones in humans are GLP-1, which is secreted mainly by L cells in the distal intestine (ileum and colon), and glucose-dependent insulinotropic polypeptide from K cells of the small intestine (duodenum and proximal jejunum).23 Both peptides are released from the gastrointestinal tract in response to meal ingestion, and both are reported to play a major role in nutrient uptake. One of the key observations for incretins was the demonstration of the “incretin effect,” which
INCRETIN MODALITIES AS THERAPY FOR T2DM
Despite the promise of GLP-1 as a modality in humans, GLP-1 is not considered to be a practical incretin therapy that can be used for the treatment of T2DM based on its secretion and metabolism, which is outlined schematically in Figure 2.24., 25., 26. As aforementioned, GLP-1 is released predominantly by the L cells in the small intestine into the plasma in its active form and becomes rapidly inactivated by an enzyme that has been termed DPP-4 (Figure 2). On the basis of the observation of
DPP-4 Inhibitors
As outlined earlier, one mechanism by which one could increase endogenous GLP-1 activity is to inhibit the activity of DPP-4, the enzyme that rapidly converts GLP-1 to its inactive state, thereby increasing the levels of GLP-1 (Figure 2). Such a strategy provides a rationale for the use of DPP-4 inhibitors, oral agents that are also called “incretin enhancers.” Sitagliptin, linagliptin vildagliptin and saxagliptin are already available in many countries and are representative compounds of the
NOVEL THERAPEUTIC APPROACHES: THE KIDNEY AS A NEW TARGET FOR DIABETIC THERAPIES
It seems that the next class of agents that will be available for the clinical treatment of T2DM may involve those that address abnormalities in the kidney. It is well known that the kidney plays a major role in carbohydrate metabolism based on its role in gluconeogenesis and because of the glomerular filtration and reabsorption of glucose in the proximal convoluted tubules. As recently reported, the kidney filters approximately 180 g of glucose daily for a normal healthy adult, and the
CONCLUSIONS
Over the recent past, considerably new information has been reported in regard to the need and approach to treat individuals with T2DM. New therapies that improve glycemic control and have favorable effects to address the unmet clinical problems are now commercially available, and many are still in development. The current approach to treatment is one that has a goal to meet the recommended glycemic targets by improving the key metabolic abnormalities associated with T2DM. The treatment regimen
REFERENCES (48)
- et al.
Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake
Metabolism
(1989) Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations
Endocrinol Metab Clin North Am
(2005)Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue
Mol Cell Endocrinol
(2009)- et al.
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Lancet
(2009) - et al.
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
Lancet
(2009) - et al.
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
N Engl J Med
(2005) - et al.
10-Year follow-up of intensive glucose control in type 2 diabetes
N Engl J Med
(2008) Standards of medical care in diabetes—2011
Diabetes Care
(2011)- et al.
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
JAMA
(2002) Effects of intensive glucose lowering in type 2 diabetes
N Engl J Med
(2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
N Engl J Med
Glucose control and vascular complications in veterans with type 2 diabetes
N Engl J Med
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial
Diabetes Care
Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents
Clin Pharmacol Ther
The physiologic role of incretin hormones: clinical applications [review]
J Am Osteopath Assoc
Redefining treatment success in type 2 diabetes mellitus: comprehensive targeting of core defects
Cleve Clin J Med
Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Recommendations from the Global Partnership for Effective Diabetes Management
Int J Clin Pract
Need for intensive, early glycaemic control in patients with type 2 diabetes
Br J Cardiol
Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management
Int J Clin Pract
Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion
N Engl J Med
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus
Diabetes
Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics
Diabetes
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus
Arch Intern Med
Diabetes: HOME reveals new data on a cornerstone of treatment
Nat Rev Endocrinol
Cited by (0)
This paper was presented as part of the Joint Plenary Session Symposium, which was held at the annual Southern Regional Meeting on February 18, 2011, New Orleans, Louisiana.